Baudax Bio, Inc. (BXRX) Research

Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.

Market snapshot

Symbol
BXRX
Price
$0.02
Day change
+7.39%
Market cap
$4.4K
P/E ratio
-0.00x
52-week range
0.0137-3.4699
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Bellicum Pharmaceuticals, Inc. (BLCM)
  • CohBar, Inc. (CWBR)
  • Altamira Therapeutics Ltd. (CYTO)
  • Impel Pharmaceuticals Inc. (IMPL)
  • Infinity Pharmaceuticals, Inc. (INFIQ)
  • Lucy Scientific Discovery Inc. (LSDI)
  • 9 Meters Biopharma, Inc. (NMTRQ)
  • InVivo Therapeutics Holdings Corporation (NVIV)

Recent insider activity

  • McAndrew Natalie — trade (0 shares) on 2023-10-09
  • Kim Yong Chan — trade (0 shares) on 2023-07-03
  • Kim Yong Chan — trade (4520066 shares) on 2023-07-03
  • HENWOOD GERALDINE — P-Purchase (1200 shares) on 2022-12-15
  • Ashton William — A-Award (39473 shares) on 2022-06-15

Open Baudax Bio, Inc. (BXRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.